NasdaqCM - Delayed Quote USD

Corcept Therapeutics Incorporated (CORT)

22.80 +0.59 (+2.66%)
At close: April 26 at 4:00 PM EDT
21.90 -0.90 (-3.95%)
After hours: April 26 at 7:33 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Joseph K. Belanoff M.D. Co-Founder, President, CEO & Director 2.43M -- 1957
Mr. Atabak Mokari CFO & Treasurer 863.03k -- 1977
Mr. Sean Maduck President of Endocrinology 1.05M 2.7M 1977
Dr. William Guyer Pharm.D. Chief Development Officer 1.03M 135k 1968
Mr. Gary Charles Robb Chief Business Officer & Secretary 1.08M 3.01M 1963
Mr. Joseph Douglas Lyon Chief Accounting & Technology Officer -- -- 1978
Dr. Hazel Hunt Ph.D. Chief Scientific Officer 895.16k 1.75M 1960
Ms. Amy Flood Chief Human Resources & Communications Officer -- -- --
Ms. Monica Tellado President of Emerging Markets -- -- 1973
Mr. Roberto W. Vieira President of Oncology -- -- --

Corcept Therapeutics Incorporated

149 Commonwealth Drive
Menlo Park, CA 94025
United States
650 327 3270 https://www.corcept.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
352

Description

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Corporate Governance

Corcept Therapeutics Incorporated’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 6; Compensation: 8.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 01, 2024
Corcept Therapeutics Incorporated Earnings Call

Related Tickers

CYTK Cytokinetics, Incorporated
65.34
+0.83%
 
IMVT Immunovant, Inc.
27.17
-2.09%
 
JANX Janux Therapeutics, Inc.
47.39
+0.62%
 
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%
 
KURA Kura Oncology, Inc.
19.65
+3.42%
 
BBIO BridgeBio Pharma, Inc.
24.88
+2.26%
 
BPMC Blueprint Medicines Corporation
93.00
+2.50%
 
APLS Apellis Pharmaceuticals, Inc.
49.86
+4.03%
 
CGEM Cullinan Therapeutics, Inc.
25.30
+31.43%
 
PTCT PTC Therapeutics, Inc.
28.57
+12.08%